Novo Nordisk, the pharmaceutical company responsible for producing many GLP-1 receptor agonist medications, including Ozempic, Wegovy, and Saxenda, reported an annual profit equivalent to over $12 billion in 2023.51 Ozempic contributed significantly to this revenue, accounting for 41% of total sales in 2023 and totaling nearly $14 billion.51 Mounjaro is expected to outperform Ozempic as the top-selling drug in the obesity and diabetes markets, with projected sales of $27 billion by 2029.52 The popularization of the term “Ozempic® face” in media outlets exemplifies this. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.